EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

Ashwin Somasundaram, Timothy F Burns

Lung Cancer: Targets and Therapy · 2017

DOI: 10.2147/lctt.s105678 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Lung Cancer: Targets and Therapy, 2017. Verfasst von Ashwin Somasundaram und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

NSCLCprogrammed death 1programmed death ligand 1regulatory T-cellstumor-infiltrating lymphocytes

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.

Zitieren

APA

Somasundaram, A., & Burns, T. F. (2017). Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Lung Cancer: Targets and Therapy. https://doi.org/10.2147/lctt.s105678

Vancouver

Somasundaram A, Burns TF. Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. Lung Cancer: Targets and Therapy. 2017. doi:10.2147/lctt.s105678

BibTeX
@article{Somasundaram2017,
  author = {Somasundaram, Ashwin and Burns, Timothy F},
  title = {Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives},
  journal = {Lung Cancer: Targets and Therapy},
  year = {2017},
  doi = {10.2147/lctt.s105678}
}
Kostenlos starten →